Also Big Pharma has the political throw weight to get the FDA to more quickly offer label extensions to use DCVax-L on other operable solid tumors (if it is safe in the brain it is safe anywhere) while NWBO would have to fight tooth and nail to get the same approvals.
Thus DCVax-L in the hands of Big Pharma is a much more valuable product than it is in the hands of beleaguered NWBO which even with approval has a good chance of collapsing like DNDN since MWBO management simply cannot handle the regulators, media, or insurance companies, either here or in Germany. A Big Pharma firm, by contrast is excellent in all those areas.
A buyout at a truly fair price would benefit all concerned but I doubt that either side is capable of negotiating in good faith.
News 
Market Data 
Discover 
